Head to Head Contrast: Nautilus Biotechnology (NASDAQ:NAUT) & OnKure Therapeutics (NASDAQ:OKUR)

OnKure Therapeutics (NASDAQ:OKUR) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Profitability

This table compares OnKure Therapeutics and Nautilus Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-74.86%	-67.92%
Nautilus Biotechnology	N/A	-33.35%	-28.41%

Earnings and Valuation

This table compares OnKure Therapeutics and Nautilus Biotechnology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$52.67 million	($4.79)	-0.63
Nautilus Biotechnology	N/A	N/A	-$70.78 million	($0.50)	-3.66

Nautilus Biotechnology is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

OnKure Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for OnKure Therapeutics and Nautilus Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1	1	3	0	2.40
Nautilus Biotechnology	1	0	0	0	1.00

OnKure Therapeutics presently has a consensus target price of $32.00, indicating a potential upside of 963.12%. Nautilus Biotechnology has a consensus target price of $2.50, indicating a potential upside of 36.61%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than Nautilus Biotechnology.

Institutional and Insider Ownership

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

OnKure Therapeutics beats Nautilus Biotechnology on 6 of the 11 factors compared between the two stocks.

About OnKure Therapeutics

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.